Metabolism as a key to histone deacetylase inhibition

References

• Abbas A, Gupta S. 2008. The role of histone deacetylases in prostate cancer. Epigenetics 3:300–309.
   PubMed Web of Science ®Google Scholar
• Adenuga D, Yao H, March TH, Seagrave J, Rahman I. 2009. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 40:464–473.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. 2010. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173–199.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Ichikawa H. 2005. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4:1201–1215.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Sakr WA, Rahman KM. 2010. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 11:652–666.
   PubMed Web of Science ®Google Scholar
• Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH, Smoot D. 2009. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 54:2109–2117.
   PubMed Web of Science ®Google Scholar
• Assisi RF; GISDI Study Group. 2008. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild–moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 54:231–238.
   PubMedGoogle Scholar
• Balakrishnan L, Milavetz B. 2010. Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Biol 45:440–452.
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729–26734.
   PubMed Web of Science ®Google Scholar
• Bang MH, Chio OS, Kim WK. 2007. Soy oligosaccharide increases fecal bifidobacteria counts, short-chain fatty acids, and fecal lipid concentrations in young Korean women. J Med Food 10:366–370.
   Google Scholar
• Barnes PJ. 2010a. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 19:330–338.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. 2010b. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120:76–85.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. 2009. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71:451–464.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Epelbaum R, Schaffer M. 2010. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17:190–197.
   PubMed Web of Science ®Google Scholar
• Batra S, Sahu RP, Kandala PK, Srivastava SK. 2010. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther 9:1596–1608.
   Google Scholar
• Biancotto C, Frigè G, Minucci S. 2010. Histone modification therapy of cancer. Adv Genet 70:341–386.
   PubMedGoogle Scholar
• Bird AR, Vuaran MS, King RA, Noakes M, Keogh J, Morell MK, Topping DL. 2008. Wholegrain foods made from a novel high-amylose barley variety (Himalaya 292) improve indices of bowel health in human subjects. Br J Nutr 99:1032–1040.
   PubMed Web of Science ®Google Scholar
• Boffa LC, Vidali G, Mann RS, Allfrey VG. 1978. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253:3364–3366.
   PubMed Web of Science ®Google Scholar
• Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A. 2008. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 283:26694–26704.
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Lanpher B, Erez A, Ananieva EA, Islam M, Marini JC, Sun Q, Yu C, Hegde M, Li J, Wynn RM, Chuang DT, Hutson S, Lee B. 2010. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet 20:631–640.
   Google Scholar
• Bush EW, McKinsey TA. 2010. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 106:272–284.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, Bates TE, Giuffrida Stella AM, Schapira T, Dinkova Kostova AT, Rizzarelli E. 2008. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 33:2444–2471.
   PubMed Web of Science ®Google Scholar
• Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429:273–282.
   PubMed Web of Science ®Google Scholar
• Cheung KL, Kong AN. 2010. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12:87–97.
   PubMed Web of Science ®Google Scholar
• Chi P, Allis CD, Wang GG. 2010. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10:457–469.
   PubMed Web of Science ®Google Scholar
• Cho YS, Whitehead L, Li J, Chen CH, Jiang L, Vögtle M, Francotte E, Richert P, Wagner T, Traebert M, Lu Q, Cao X, Dumotier B, Fejzo J, Rajan S, Wang P, Yan-Neale Y, Shao W, Atadja P, Shultz M. 2010. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J Med Chem 53:2952–2963.
   Google Scholar
• Chou CJ, Herman D, Gottesfeld JM. 2008. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 283:35402–35409.
   PubMed Web of Science ®Google Scholar
• Choudhury M, Shukla SD. 2008. Surrogate alcohols and their metabolites modify histone H3 acetylation: involvement of histone acetyl transferase and histone deacetylase. Alcohol Clin Exp Res 32:829–839.
   PubMed Web of Science ®Google Scholar
• Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. 2010. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501:79–90.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Dashwood RH, Ho E. 2008. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269:291–304.
   PubMed Web of Science ®Google Scholar
• Colussi C, Illi B, Rosati J, Spallotta F, Farsetti A, Grasselli A, Mai A, Capogrossi MC, Gaetano C. 2010. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res 62:3–10.
   Google Scholar
• Corfe BM, Williams EA, Bury JP, Riley SA, Croucher LJ, Lai DY, Evans CA. 2009. A study protocol to investigate the relationship between dietary fibre intake and fermentation, colon cell turnover, global protein acetylation and early carcinogenesis: the FACT study. BMC Cancer 9:332.
   Google Scholar
• Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums. 2009. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10:99–106.
   PubMed Web of Science ®Google Scholar
• Dashwood RH, Ho E. 2007. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17:363–369.
   PubMed Web of Science ®Google Scholar
• Dashwood RH, Myzak MC, Ho E. 2006. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27:344–349.
   PubMed Web of Science ®Google Scholar
• Davis CD, Ross SA. 2007. Dietary components impact histone modifications and cancer risk. Nutr Rev 65:88–94.
   Google Scholar
• Davis CD, Ross SA. 2008. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev 66:477–482.
   PubMed Web of Science ®Google Scholar
• Delage B, Dashwood RH. 2008. Dietary manipulation of histone structure and function. Annu Rev Nutr 28:347–366.
   Web of Science ®Google Scholar
• Delage B, Dashwood RH. 2009a. Targeting the epigenome with dietary agents. In: Surh Y-J, ed. Dietary Modulation of Cell Signaling Pathways. Boca Raton, FL: CRC Press, Vol. 13, pp. 337–369.
   Google Scholar
• Delage B, Dashwood RH. 2009b. Nutrients, histone modifications, and chromatin remodeling in chronic inflammation. In: Choi S-W, Frisco S, eds. Nutrients and Epigenetics. Boca Raton, FL: CRC Press, Vol. 6, pp. 127–154.
   Google Scholar
• Dempe JS, Pfeiffer E, Grimm AS, Metzler M. 2008. Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells. Mol Nutr Food Res 52:1074–1081.
   PubMed Web of Science ®Google Scholar
• Denu JM. 2007. Vitamins and aging: pathways to NAD+ synthesis. Cell 129:453–454.
   PubMed Web of Science ®Google Scholar
• Desai D, Salli U, Vrana KE, Amin S. 2010. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 20:2044–2047.
   Google Scholar
• Dietz KC, Casaccia P. 2010. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 62:11–17.
   PubMed Web of Science ®Google Scholar
• Ding H, Dolan PJ, Johnson GV. 2008. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106:2119–2130.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Talalay P. 2008. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 52 (Suppl 1):S128–S138.
   Google Scholar
• Dittenhafer-Reed KE, Feldman JL, Denu JM. 2010. Catalysis and mechanistic insights into sirtuin activation. Chembiochem 12:281–289.
   Google Scholar
• Donmez G, Guarente L. 2010. Aging and disease: connections to sirtuins. Aging Cell 9:285–290.
   PubMed Web of Science ®Google Scholar
• Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW. 2008. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 47:13554–13563.
   PubMed Web of Science ®Google Scholar
• Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duée PH, Martel P, Chaumontet C. 2004a. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25:1227–1236.
   PubMed Web of Science ®Google Scholar
• Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duée PH, Martel P, Chaumontet C. 2004b. Repetitive treatments of colon HT-29 cells with diallyl disulfide induce a prolonged hyperacetylation of histone H3 K14. Ann N Y Acad Sci 1030:612–621.
   Google Scholar
• Druesne-Pecollo N, Chaumontet C, Latino-Martel P. 2008. Diallyl disulfide increases histone acetylation in colon cells in vitro and in vivo. Nutr Rev 66 (Suppl 1):S39–S41.
   Google Scholar
• Druesne-Pecollo N, Chaumontet C, Pagniez A, Vaugelade P, Bruneau A, Thomas M, Cherbuy C, Duée PH, Martel P. 2007. In vivo treatment by diallyl disulfide increases histone acetylation in rat colonocytes. Biochem Biophys Res Commun 354:140–147.
   Google Scholar
• Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39.
   PubMed Web of Science ®Google Scholar
• Ebbel EN, Leymarie N, Schiavo S, Sharma S, Gevorkian S, Hersch S, Matson WR, Costello CE. 2010. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 399:152–161.
   PubMed Web of Science ®Google Scholar
• Elaut G, Török G, Vinken M, Laus G, Papeleu P, Tourwe D, Rogiers V. 2002. Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 30:1320–1328.
   PubMed Web of Science ®Google Scholar
• Epstein J, Sanderson IR, Macdonald TT. 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103:1545–1557.
   PubMed Web of Science ®Google Scholar
• Ernst IM, Wagner AE, Schuemann C, Storm N, Höppner W, Döring F, Stocker A, Rimbach G. 2010. Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblasts. Pharmacol Res 63:233–240.
   Google Scholar
• Fang M, Chen D, Yang CS. 2007. Dietary polyphenols may affect DNA methylation. J Nutr 123 (Suppl 1):223S–228S.
   Google Scholar
• Ficner R. 2009. Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem 9:235–240.
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193.
   PubMed Web of Science ®Google Scholar
• Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. 2010. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol 28:3623–3629.
   PubMed Web of Science ®Google Scholar
• Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, Kristiansen G. 2008. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381.
   Google Scholar
• Fu S, Kurzrock R. 2010. Development of curcumin as an epigenetic agent. Cancer 116:4670–4676.
   PubMed Web of Science ®Google Scholar
• Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916–4921.
   PubMed Web of Science ®Google Scholar
• Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S. 1995. Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells. Oncogene 10:1119–1123.
   PubMedGoogle Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. 2009. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052–2058.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, Prasad PD. 2008. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10:193–199.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. 2009. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29–40.
   PubMed Web of Science ®Google Scholar
• Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. 2005. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem 280:556–563.
   PubMed Web of Science ®Google Scholar
• Gilbert ER, Liu D. 2010. Flavonoids influence epigenetic-modifying enzyme activity: structure–function relationships and the therapeutic potential for cancer. Curr Med Chem 17:1756–1768.
   PubMed Web of Science ®Google Scholar
• Göttlicher M. 2004. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83 (Suppl 1):S91–S92.
   Google Scholar
• Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ, Kucuk O. 2010. Cancer prevention with natural compounds. Semin Oncol 37:258–281.
   PubMed Web of Science ®Google Scholar
• Gurard-Levin ZA, Kilian KA, Kim J, Bähr K, Mrksich M. 2010. Peptide arrays identify isoform-selective substrates for profiling endogenous lysine deacetylase activity. ACS Chem Biol 5:863–873.
   PubMed Web of Science ®Google Scholar
• Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, Troost FJ, Venema K, Brummer RJ. 2009. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28:88–93.
   PubMed Web of Science ®Google Scholar
• Han SH. 2009. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 5:120–125.
   PubMed Web of Science ®Google Scholar
• Hanai H, Sugimoto K. 2009. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 15:2087–2094.
   PubMed Web of Science ®Google Scholar
• Handel AE, Ramagopalan SV. 2010. Is Lamarckian evolution relevant to medicine? BMC Med Genet 11:73.
   PubMed Web of Science ®Google Scholar
• Higdon JV, Delage B, Williams DE, Dashwood RH. 2007. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55:224–236.
   PubMed Web of Science ®Google Scholar
• Hockenbery DM. 2010. Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51:476–489.
   PubMed Web of Science ®Google Scholar
• Hoehle SI, Pfeiffer E, Metzler M. 2007. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res 51:932–938.
   PubMed Web of Science ®Google Scholar
• Hogarth P, Lovrecic L, Krainc D. 2007. Sodium phenylbutyrate in Huntington’s disease: a dose-finding study. Mov Disord 22:1962–1964.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. 2010. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood 116:2732–2741.
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458.
   PubMed Web of Science ®Google Scholar
• Huber K, Schemies J, Uciechowska U, Wagner JM, Rumpf T, Lewrick F, Süss R, Sippl W, Jung M, Bracher F. 2010. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins). J Med Chem 53:1383–1386.
   PubMed Web of Science ®Google Scholar
• Iciek M, Kwiecien I, Wlodek L. 2009. Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen 50:247–265.
   PubMed Web of Science ®Google Scholar
• Imai S. 2010. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res 62:42–47.
   Google Scholar
• Imai S. 2009. SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty. Curr Opin Clin Nutr Metab Care 12:350–356.
   PubMed Web of Science ®Google Scholar
• Imai S, Guarente L. 2010. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 31:212–220.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. 2009. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27:5848–5856.
   PubMed Web of Science ®Google Scholar
• Israelsen WJ, Vander Heiden MG. 2010. ATP consumption promotes cancer metabolism. Cell 143:669–671.
   PubMed Web of Science ®Google Scholar
• Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H. 1990. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43:1524–1532.
   PubMed Web of Science ®Google Scholar
• Izzotti A, Larghero P, Balansky R, Pfeffer U, Steele VE, De Flora S. 2010. Interplay between histopathological alterations, cigarette smoke and chemopreventive agents in defining microRNA profiles in mouse lung. Mutat Res. Oct 23 [Epub ahead of print].
   Google Scholar
• Jackson MI, Combs GF Jr. 2008. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11:718–726.
   PubMed Web of Science ®Google Scholar
• Jiang S, Ma X, Huang Y, Xu Y, Zheng R, Chiao JW. 2010. Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol 3:48.
   PubMedGoogle Scholar
• Jones P, Steinkühler C. 2008. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des 14:545–561.
   Google Scholar
• Juge N, Mithen RF, Traka M. 2007. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64:1105–1127.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. 2010. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150:72–82.
   PubMed Web of Science ®Google Scholar
• Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfield E, Ratain MJ. 2010. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics 20:638–641.
   PubMed Web of Science ®Google Scholar
• Kekatpure VD, Dannenberg AJ, Subbaramaiah K. 2009. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 284:7436–7445.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O’Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578–3588.
   PubMed Web of Science ®Google Scholar
• Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429–22435.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim M, Kwon HJ. 2003. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110–119.
   PubMedGoogle Scholar
• Krainc D. 2010. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol 67:388–392.
   Google Scholar
• Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, Purgatto E, Ong TP, Moreno FS. 2009. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 124:2520–2527.
   PubMed Web of Science ®Google Scholar
• Kwak MK, Kensler TW. 2010. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66–76.
   PubMed Web of Science ®Google Scholar
• Kyrylenko S, Baniahmad A. 2010. Sirtuin family: a link to metabolic signaling and senescence. Curr Med Chem 17:2921–2932.
   Google Scholar
• LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. 2009. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2:67.
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. 2009. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459–5468.
   PubMed Web of Science ®Google Scholar
• Lawless MW, O’Byrne KJ, Gray SG. 2009. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? Curr Diabetes Rev 5:201–209.
   Google Scholar
• Lea MA, Randolph VM. 2001. Induction of histone acetylation in rat liver and hepatoma by organosulfur compounds including diallyl disulfide. Anticancer Res 21:2841–2845.
   PubMed Web of Science ®Google Scholar
• Lea MA, Randolph VM, Hodge SK. 1999a. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971–1976.
   PubMed Web of Science ®Google Scholar
• Lea MA, Randolph VM, Patel M. 1999b. Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Int J Oncol 15:347–352.
   PubMed Web of Science ®Google Scholar
• Lea MA, Randolph VM, Lee JE, desBordes C. 2001. Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int J Cancer 92:784–789.
   PubMed Web of Science ®Google Scholar
• Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C. 2002. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 43:90–102.
   PubMed Web of Science ®Google Scholar
• Leder A, Leder P. 1975. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5:319–322.
   PubMed Web of Science ®Google Scholar
• Lee JI, Nian H, Cooper AJ, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT. 2009. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila) 2:683–693.
   PubMed Web of Science ®Google Scholar
• Lee JS, Smith E, Shilatifard A. 2010a. The language of histone crosstalk. Cell 142:682–685.
   PubMed Web of Science ®Google Scholar
• Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, Cuervo AM, Yao TP. 2010b. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29:969–980.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS. 2002. Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11:1025–1032.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Shim JY, Zhu BT. 2005. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 68:1018–1030.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Guo B. 2010a. Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 70:646–654.
   PubMed Web of Science ®Google Scholar
• Li Y, Kong D, Wang Z, Sarkar FH. 2010b. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 27:1027–1041.
   PubMed Web of Science ®Google Scholar
• Li Y, Tollefsbol TO. 2010. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 17:2141–2151.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. 2009. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39–51.
   PubMed Web of Science ®Google Scholar
• Lü J, Jiang C. 2005. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 7:1715–1727.
   PubMed Web of Science ®Google Scholar
• Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T. 2010. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 53:2569–2578.
   Google Scholar
• Ma H, Nguyen C, Lee KS, Kahn M. 2005. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24:3619–3631.
   PubMed Web of Science ®Google Scholar
• Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW. 2006. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 28:1287–1293.
   Google Scholar
• Mariadason JM. 2008. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28–37.
   PubMed Web of Science ®Google Scholar
• Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84–90.
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. 2009. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600–608.
   PubMed Web of Science ®Google Scholar
• Marwick JA, Adcock IM, Chung KF. 2010. Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches. Drugs 70:929–948.
   Google Scholar
• Masuoka Y, Shindoh N, Inamura N. 2008. Histone deacetylase inhibitors from microorganisms: the Astellas experience. Prog Drug Res 66:335, 337–335, 359.
   Google Scholar
• Matthias P, Yoshida M, Khochbin S. 2008. HDAC6 a new cellular stress surveillance factor. Cell Cycle 7:7–10.
   PubMed Web of Science ®Google Scholar
• Meeran SM, Patel SN, Tollefsbol TO. 2010. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5:e11457.
   PubMed Web of Science ®Google Scholar
• Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, Marwick JA, Chakravarty P, Fletcher D, Whittaker P, Megson IL, Kirkham PA, Rahman I. 2008. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 39:312–323.
   PubMed Web of Science ®Google Scholar
• Mercurio C, Minucci S, Pelicci PG. 2010. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62:18–34.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51.
   PubMed Web of Science ®Google Scholar
• Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S. 2008. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923–1930.
   PubMed Web of Science ®Google Scholar
• Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O; German Working Group Trace Elements and Electrolytes in Oncology. 2010. Selenium or no selenium—that is the question in tumor patients: a new controversy. Integr Cancer Ther 9:136–141.
   PubMed Web of Science ®Google Scholar
• Murugan RS, Vinothini G, Hara Y, Nagini S. 2009. Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res 29:2301–2305.
   PubMed Web of Science ®Google Scholar
• Myzak MC, Dashwood RH. 2006a. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett 233:208–218.
   PubMed Web of Science ®Google Scholar
• Myzak MC, Dashwood RH. 2006b. Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 7:443–452.
   PubMed Web of Science ®Google Scholar
• Myzak MC, Ho E, Dashwood RH. 2006. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 45:443–446.
   Google Scholar
• Myzak MC, Karplus PA, Chung FL, Dashwood RH. 2004. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64:5767–5774.
   PubMed Web of Science ®Google Scholar
• Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. 2007. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 232:227–234.
   PubMed Web of Science ®Google Scholar
• Nian H, Delage B, Ho E, Dashwood RH. 2009a. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen 50:213–221.
   PubMed Web of Science ®Google Scholar
• Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. 2009b. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 30:1416–1423.
   PubMed Web of Science ®Google Scholar
• Nian H, Delage B, Pinto JT, Dashwood RH. 2008. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29:1816–1824.
   PubMed Web of Science ®Google Scholar
• Nilsson AC, Östman EM, Knudsen KE, Holst JJ, Björck IM. 2010. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J Nutr 140:1932–1936.
   PubMed Web of Science ®Google Scholar
• Noureen N, Rashid H, Kalsoom S. 2010. Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 66:625–633.
   PubMed Web of Science ®Google Scholar
• Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL, Zaizov R. 1983. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51:9–14.
   Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166–173.
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. 2009a. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 18:1605–1617.
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O. 2009b. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15:91–99.
   PubMed Web of Science ®Google Scholar
• Oger F, Lecorgne A, Sala E, Nardese V, Demay F, Chevance S, Desravines DC, Aleksandrova N, Le Guével R, Lorenzi S, Beccari AR, Barath P, Hart DJ, Bondon A, Carettoni D, Simonneaux G, Salbert G. 2010. Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring. J Med Chem 53:1937–1950.
   Google Scholar
• Ohta Y, Suzuki KT. 2008. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol 226:169–177.
   PubMed Web of Science ®Google Scholar
• Oki Y, Issa JP. 2006. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1:169–182.
   PubMedGoogle Scholar
• Ortore G, Di Colo F, Martinelli A. 2009. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. J Chem Inf Model 49:2774–2785.
   Google Scholar
• Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH. 2010. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 10:372–387.
   PubMed Web of Science ®Google Scholar
• Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859–863.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, Bang YJ, Kim TY. 2008. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 368:318–322.
   Google Scholar
• Patra SK, Patra A, Dahiya R. 2001. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287:705–713.
   PubMed Web of Science ®Google Scholar
• Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF. 2006. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22:40–49.
   PubMed Web of Science ®Google Scholar
• Pinto JT, Lee JI, Sinha R, Macewan ME, Cooper AJ. 2010. Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids. Apr 10 [Epub ahead of print].
   Google Scholar
• Pledgie-Tracy A, Sobolewski MD, Davidson NE. 2007. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6:1013–1021.
   PubMed Web of Science ®Google Scholar
• Poke FS, Qadi A, Holloway AF. 2010. Reversing aberrant methylation patterns in cancer. Curr Med Chem 17:1246–1254.
   Google Scholar
• Pool-Zobel BL, Sauer J. 2007. Overview of experimental data on reduction of colorectal cancer risk by inulin-type fructans. J Nutr 137:2580S–2584S.
   PubMed Web of Science ®Google Scholar
• Powolny AA, Singh SV. 2008. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett 269:305–314.
   PubMed Web of Science ®Google Scholar
• Rahman I. 2008. Dietary polyphenols mediated regulation of oxidative stress and chromatin remodeling in inflammation. Nutr Rev 66 (Suppl 1):S42–S45.
   Google Scholar
• Rajendrasozhan S, Yao H, Rahman I. 2009. Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 6:291–297.
   PubMedGoogle Scholar
• Ramadori G, Coppari R. 2010. Pharmacological manipulations of CNS sirtuins: potential effects on metabolic homeostasis. Pharmacol Res 62:48–54.
   Google Scholar
• Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. 2010. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28:4507–4512.
   PubMed Web of Science ®Google Scholar
• Riggs MG, Whittaker RG, Neumann JR, Ingram VM. 1977. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462–464.
   PubMed Web of Science ®Google Scholar
• Rivieccio MA, Brochier C, Willis DE, Walker BA, D’Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, Ratan RR, Langley B. 2009. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106:19599–19604.
   PubMed Web of Science ®Google Scholar
• Ross SA, Milner JA. 2007. Epigenetic modulation and cancer: effect of metabolic syndrome? Am J Clin Nutr 86:s872–s877.
   Google Scholar
• Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, Ferrante RJ. 2005. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93:1087–1098.
   PubMed Web of Science ®Google Scholar
• Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R. 2007. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 21:2344–2353.
   PubMed Web of Science ®Google Scholar
• Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM. 2004. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32:1132–1138.
   PubMed Web of Science ®Google Scholar
• Santini V, Gozzini A, Ferrari G. 2007. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8:383–393.
   PubMed Web of Science ®Google Scholar
• Sattler UG, Hirschhaeuser F, Mueller-Klieser WF. 2010. Manipulation of glycolysis in malignant tumors: fantasy or therapy? Curr Med Chem 17:96–108.
   PubMed Web of Science ®Google Scholar
• Savickiene J, Treigyte G, Vistartaite G, Tunaitis V, Magnusson KE, Navakauskiene R. 2010. C/EBPa and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling. Differentiation 81:57–67.
   Google Scholar
• Schantz M, Erk T, Richling E. 2010. Metabolism of green tea catechins by the human small intestine. Biotechnol J 5:1050–1059.
   PubMed Web of Science ®Google Scholar
• Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. 2008. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 283:11355–11363.
   PubMed Web of Science ®Google Scholar
• Sekhavat A, Sun JM, Davie JR. 2007. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 85:751–758.
   PubMed Web of Science ®Google Scholar
• Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, Verma A. 2010. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2:654–669.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847–6854.
   PubMed Web of Science ®Google Scholar
• Sies H. 2010. Polyphenols and health: update and perspectives. Arch Biochem Biophys 501:2–5.
   PubMed Web of Science ®Google Scholar
• Silva JP, Wahlestedt C. 2010. Role of sirtuin 1 in metabolic regulation. Drug Discov Today 15:781–791.
   PubMed Web of Science ®Google Scholar
• Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. 2010a. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10:935–954.
   PubMed Web of Science ®Google Scholar
• Singh N, Thangaraju M, Prasad PD, Martin PM, Lambert NA, Boettger T, Offermanns S, Ganapathy V. 2010b. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem 285:27601–27608.
   PubMed Web of Science ®Google Scholar
• Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW. 2004. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12:1325–1334.
   PubMed Web of Science ®Google Scholar
• Stahl SM. 2010. Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr 15:358–365.
   Google Scholar
• Stalmach A, Mullen W, Steiling H, Williamson G, Lean ME, Crozier A. 2010a. Absorption, metabolism, and excretion of green tea flavan-3-ols in humans with an ileostomy. Mol Nutr Food Res 54:323–334.
   PubMed Web of Science ®Google Scholar
• Stalmach A, Steiling H, Williamson G, Crozier A. 2010b. Bioavailability of chlorogenic acids following acute ingestion of coffee by humans with an ileostomy. Arch Biochem Biophys 501:98–105.
   PubMed Web of Science ®Google Scholar
• Steward WP, Gescher AJ. 2008. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 52:1005–1009.
   Google Scholar
• Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, Yamori T, Tsumoto H, Nakagawa H, Miyata N. 2009. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J Med Chem 52:2909–2922.
   Google Scholar
• Suzuki T, Kouketsu A, Matsuura A, Kohara A, Ninomiya S, Kohda K, Miyata N. 2004. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 14:3313–3317.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N. 2005. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem 48:1019–1032.
   PubMedGoogle Scholar
• Thangaraju M, Carswell KN, Prasad PD, Ganapathy V. 2009a. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417:379–389.
   PubMed Web of Science ®Google Scholar
• Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, Ganapathy V. 2009b. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115:4655–4666.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Suzuki N, T Suzuki K, Ogra Y. 2009. Selenium metabolism in rats with long-term ingestion of Se-methylselenocysteine using enriched stable isotopes. J Toxicol Sci 34:191–200.
   Google Scholar
• Valgimigli L, Iori R. 2009. Antioxidant and pro-oxidant capacities of ITCs. Environ Mol Mutagen 50:222–237.
   PubMed Web of Science ®Google Scholar
• Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkühler C, Di Marco S. 2004. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101:15064–15069.
   PubMed Web of Science ®Google Scholar
• Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carfí A, De Francesco R, Steinkühler C, Di Marco S. 2007. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex. EMBO Rep 8:879–884.
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. 2010. Modifying chromatin architecture during the response to DNA breakage. Crit Rev Biochem Mol Biol 45:2–13.
   PubMed Web of Science ®Google Scholar
• Verkerk R, Schreiner M, Krumbein A, Ciska E, Holst B, Rowland I, De Schrijver R, Hansen M, Gerhäuser C, Mithen R, Dekker M. 2009. Glucosinolates in Brassica vegetables: the influence of the food supply chain on intake, bioavailability and human health. Mol Nutr Food Res 53 (Suppl 2):S219.
   Google Scholar
• Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. 2008a. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 19:587–593.
   PubMed Web of Science ®Google Scholar
• Waldecker M, Kautenburger T, Daumann H, Veeriah S, Will F, Dietrich H, Pool-Zobel BL, Schrenk D. 2008b. Histone-deacetylase inhibition and butyrate formation: fecal slurry incubations with apple pectin and apple juice extracts. Nutrition 24:366–374.
   PubMed Web of Science ®Google Scholar
• Wang D. 2009. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 9:241–256.
   PubMed Web of Science ®Google Scholar
• Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW. 2008. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33:375–380.
   PubMed Web of Science ®Google Scholar
• Warburg O. 1956. On the origin of cancer cells. Science 123:309–314.
   PubMed Web of Science ®Google Scholar
• Weng JR, Tsai CH, Kulp SK, Chen CS. 2008. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett 262:153–163.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. 2010. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. 2010. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 65:979–988.
   PubMed Web of Science ®Google Scholar
• Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689.
   PubMed Web of Science ®Google Scholar
• Xiao L, Huang Y, Zhen R, Chiao JW, Liu D, Ma X. 2010. Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol 123:71–76.
   Google Scholar
• Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. 2009. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 125:774–782.
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Omi Y, Fujii N, Ozaki A, Nakama A, Sakakibara Y, Suiko M, Nishiyama K. 2009. Mustard oil in “Shibori Daikon” a variety of Japanese radish, selectively inhibits the proliferation of H-ras-transformed 3Y1 cells. Biosci Biotechnol Biochem 73:2217–2221.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. 2003. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103:572–576.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. 2008. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206–218.
   PubMed Web of Science ®Google Scholar
• Yap KL, Zhou MM. 2010. Keeping it in the family: diverse histone recognition by conserved structural folds. Crit Rev Biochem Mol Biol 45:488–505.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Sugita K. 1992. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells. Jpn J Cancer Res 83:324–328.
   PubMedGoogle Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174–17179.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Matsuyama A, Komatsu Y, Nishino N. 2003. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351–2358.
   PubMedGoogle Scholar
• Yu J, Auwerx J. 2010. Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation. Pharmacol Res 62:35–41.
   PubMed Web of Science ®Google Scholar
• Zeng H, Botnen JH, Briske-Anderson M. 2010. Deoxycholic acid and selenium metabolite methylselenol exert common and distinct effects on cell cycle, apoptosis, and MAP kinase pathway in HCT116 human colon cancer cells. Nutr Cancer 62:85–92.
   Google Scholar
• Zhang Y, Talalay P, Cho CG, Posner GH. 1992. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399–2403.
   PubMed Web of Science ®Google Scholar